Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Latent TB Infection (LTBI) Guideline Updates										Related Pages
										Return to *MMWR* by Topic
**Original Guideline**
Original Guideline
Title
FormatTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection *MMWR*2000; 49 (No. RR-6)
PDFpdf icon
[350KB]
**Updates**
Updates
Title
FormatUpdate: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection*MMWR*2003; 52 (No. 31).
PDFpdf icon
[587KB]Update: Fatal and Severe Liver Injuries Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommendations — United States, 2001.*MMWR*2001; 50 (No. 34) (August 31, 2001)
PDFpdf icon
[287KB]Fatal and Severe Hepatitis Associated With Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection — New York and Georgia, 2000*MMWR*2001; 50 (No. 15) (April 20, 2001)
PDFpdf icon
[338KB]
**Archived Updates**
Archived Updates
TitleBackground: Severe and Fatal Liver Injury Connected to Latent TB Treatment
(August 30, 2001)
							
					
						Page last reviewed:  September 1, 2012					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosis
Basic TB Factsplus icon
How TB Spreads
Latent TB Infection and TB Disease
Signs & Symptoms
TB Risk Factors
Exposure to TB
TB Prevention
Vaccines
TB & HIV Coinfection
TB and Diabetes
TB Terms
Personal Storiesplus icon
Kristi
Laura
Kelcie
Tenzin
Mildred
Shaka
Kelly
Kim
Emily
Jerry
Kate
Nauman
Nicole
Thomas
Natalie
Esteban and Danielle
Deo
Kenni
Rosalie and Faith
Rick and Francene
Santos
Mabruka
Liliana
Martha
Tri
Sarah
Testing & Diagnosisplus icon
Who Should be Tested
Testing for TB Infection
Testing in BCG-Vaccinated Persons
TB Screening and Testing of Health Care Personnel
Testing During Pregnancy
Diagnosing latent TB infection and TB disease
Treatmentplus icon
Deciding When to Treat Latent TB Infection
Treatment Regimens for Latent TB Infection (LTBI)
Treatment for TB Disease
Adverse Events
TB Treatment of Persons Living with HIV
TB Treatment and Pregnancy
TB Treatment for Children
Drug-Resistant TB
Researchplus icon
TB Epidemiologic Studies Consortiumplus icon
Research Projects
Publications
TB Trials Consortiumplus icon
Study Descriptions
Background
Behavioral & Social Science Research
Health Care Settingsplus icon
TB Infection Control in Health Care Settings
Resources for TB Screening and Testing of Health Care Personnelplus icon
Frequently Asked Questions
TB in Specific Populationsplus icon
Health Disparities
Asian Persons
Black or African American Persons
Hispanic or Latino Persons
Children
Pregnancy
Correctional Facilities
People Experiencing Homelessness
International Travelers
Laboratory Informationplus icon
Drug Susceptibility Testing
False-Positive Investigation Toolkit
Interim Laboratory Biosafety Guidance for XDR *Mycobacterium* tuberculosis strains
Model Performance Evaluation Program (MPEP)
Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus icon
Executive Summary
Introduction
Background on Tests for Molecular Detection of DR
General Considerations and Principles for a Molecular DR Testing Service
Possible Scenarios and Scope of Testing for a Molecular DR Testing Service
Research Needs
General Recommendations of the Expert Panel
Communication Plan for the Report
Recommendations
References
Panel Members and CDC Participants
Appendix 1
Appendix 2
Appendix 3
The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus icon
General Considerations
General Recommendations of the Expert Panel
Recommendations to ACET, CDC, DTBE
Data & Statisticsplus icon
TB Incidence in the United States
Reported TB in the US, 2019 Surveillance Report
Trends in Tuberculosis 2019
Tuberculosis in the United States, 2019 (Slide Set)
Archived Surveillance Reports and Slide Sets
2018 State and City Report
Archived State and City Reports
Professional Resources & Toolsplus icon
Tools for Healthcare Providersplus icon
Interactive Core Curriculum on Tuberculosis: What the Clinician Should Know
Resources for TB Programsplus icon
Notice of Funding Opportunity (NOFO)
Program Evaluation
TB Centers of Excellence
Publications & Productsminus icon
Patient and Public Materials
Fact Sheetsplus icon
General
Data & Statistics
Drug-Resistant TB
Infection Control & Prevention
TB in Specific Populations
Treatment
Testing & Diagnosis
Vaccines & Immunizations
Guidelinesplus icon
Control & Elimination
Drug-Resistant TB
Infection Control & Prevention
Laboratory & Genotyping
TB & HIV
TB in Specific Populations
Testing & Diagnosis
Treatment
Vaccines & Immunizations
Archived TB Guidelines
Guides & Toolkitsplus icon
Aggregate Reports
CDC TB Surveillance Training
Core Curriculum
Effective TB Interviewing for Contact Investigation
Ethnographic Guides
False-Positive Investigation Toolkit
Forging Partnerships to Eliminate TB
Guide to Application of Genotyping
LTBI: A Guide for Primary Health Care Providers
Mantoux Tuberculin Skin Testing Products
Report of Verified Case of Tuberculosis (RVCT)
Self-Study Modules
TB Contact Investigation Interviewing Skills Course
TB eDOT Toolkit
Understanding the TB Cohort Review Process
Newslettersplus icon
TB Notes, No. 2, 2020
TB Notes, No. 1, 2020
TB Notes, No. 4, 2019
TB Notes, No. 3, 2019
TB Notes, No. 2, 2019
TB Notes, No. 1, 2019
TB Notes, No. 6, 2018
TB Notes, No. 5, 2018
TB Notes, No. 4, 2018
TB Notes, No. 3, 2018
TB Notes, No. 2, 2018
TB Notes, No. 1, 2018
TB Notes, No. 5, 2017
TB Notes, No. 4, 2017
TB Notes, No. 3, 2017
TB Notes, No. 2, 2017
TB Notes, No. 1, 2017
TB Notes, No. 5, 2016
TB Notes, No. 4, 2016
TB Notes, No. 3, 2016
TB Notes, No. 2, 2016
TB Notes, No. 1, 2016
Pamphlets, Brochures, Bookletsplus icon
Questions and Answers
Patient Education Series
Tuberculosis – Get the Facts
Tuberculosis – The Connection between TB and HIV
12-Dose Regimen for Latent TB Infection-Patient Education Brochure
Postersplus icon
Mantoux Tuberculin Skin Test Wall Chart
World TB Day
Think TB
Stop TB
Reports & Articlesminus icon
DTBE Authored Journal Articles
Tuberculosis Laboratory Aggregate Reports
Latent TB Infection (LTBI) Guideline Updates
Slide Setsplus icon
Epidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016
Self-Study Modules on Tuberculosis, 1-5 Slide Sets
The Tuberculosis (TB) in Correctional Settingsplus icon
Facilitator Guide
Introduction to TB Genotyping
Core Curriculum
Epidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017
Prevention and Control of Tuberculosis in Correctional and Detention Facilities
Guidelines for Preventing the Transmission of M. TB in Health care Settings
Investigation of Contacts of Persons with Infectious TB
Epidemiology of Pediatric Tuberculosis in the United States
Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection
Electronic Tools & Resources
Web-Based Courses & Webinarsplus icon
TB 101 for Health Care Workersplus icon
TB 101
Interactive Core Curriculum
Content Syndication
Infographicsplus icon
Social Media Graphics
Customizable Take on TB Infographic with Instructions
Events
World TB Dayplus icon
Resources
U.S. TB Championsplus icon
2020 CDC U.S. TB Elimination Champions
2019 CDC U.S. TB Elimination Champions
2018 CDC U.S. TB Elimination Champions
2017 CDC U.S. TB Elimination Champions
2016 Supporting TB Control
2016 Building Partnerships
2016 Expanding Testing and Treatment
2016 Focusing on Prevention
2016 Maximizing Resources
Activities
History
Linksplus icon
State TB Control Offices
About Usplus icon
Mission Statement and Activitiesplus icon
DTBE Strategic Plan
National TB Program Objectives
Organization Chart
Advisory Groupsplus icon
Federal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue